P. Sidaway

发表

L-Type Ca2+ Channel Sparklets Revealed by TIRF Microscopy in Mouse Urinary Bladder Smooth Muscle

N. Teramoto, P. Sidaway, 2014, PloS one.

Immunotherapy: CAR T cell therapy efficacious against B-ALL across age groups

P. Sidaway, 2018, Nature Reviews Clinical Oncology.

Immunotherapy: Novel modified T cells enable more-specific tumour targeting

P. Sidaway, 2016, Nature Reviews Clinical Oncology.

MRI improves diagnosis

P. Sidaway, 2018, Nature Reviews Clinical Oncology.

Genetics: BRCA-mutant breast/ovarian cancer revealed

P. Sidaway, 2017, Nature Reviews Clinical Oncology.

Prostate cancer: Wnt signalling induces resistance

P. Sidaway, 2015, Nature Reviews Urology.

CNS cancer: Distinct subtypes of ATRTs observed

P. Sidaway, 2016, Nature Reviews Clinical Oncology.

R-CHOP can be safely de-escalated in NHL

P. Sidaway, 2020, Nature Reviews Clinical Oncology.

Lung cancer: Anti-PD-L1 therapy: patient selection is important

P. Sidaway, 2016, Nature Reviews Clinical Oncology.

Colorectal cancer: Liquid biopsy provides highly sensitive detection of RAS mutations

P. Sidaway, 2017, Nature Reviews Clinical Oncology.

ctDNA guides anti-EGFR rechallenge

P. Sidaway, 2022, Nature Reviews Clinical Oncology.

Sigma 1 receptor stimulation protects against oxidative damage through suppression of the ER stress responses in the human lens

R. Bowater, Andrew J O Smith, I. M. Wormstone, 2012, Mechanisms of Ageing and Development.

Infection: Siderophore-based vaccine protects against E. coli infection

P. Sidaway, 2017, Nature Reviews Urology.

Breast cancer: Microenvironment mediates differential resistance

P. Sidaway, 2017, Nature Reviews Clinical Oncology.

Prevention: Relating risk factor reduction to disease risk on a global level

P. Sidaway, 2014, Nature Reviews Cardiology.

Breast Cancer: Evolution of metastatic disease revealed

P. Sidaway, 2017, Nature Reviews Clinical Oncology.

Rituximab for paediatric NHL

P. Sidaway, 2020, Nature Reviews Clinical Oncology.

Fulvestrant enables better outcomes

P. Sidaway, 2019, Nature Reviews Clinical Oncology.

Quizartinib tested in patients with high-risk AML

P. Sidaway, 2018, Nature Reviews Clinical Oncology.

Haematological cancer: Brentuximab effective in untreated Hodgkin lymphoma

P. Sidaway, 2018, Nature Reviews Clinical Oncology.

COVID-19 and cancer: what we know so far

P. Sidaway, 2020, Nature Reviews Clinical Oncology.

Prostate cancer: Little intraindividual heterogeneity in metastases

P. Sidaway, 2016, Nature Reviews Clinical Oncology.

Immunotherapy: Nivolumab-induced alterations revealed

P. Sidaway, 2017, Nature Reviews Clinical Oncology.

MSI-H: a truly agnostic biomarker?

P. Sidaway, 2019, Nature Reviews Clinical Oncology.

Immunotherapy-responsive gastric cancers identified

P. Sidaway, 2018, Nature Reviews Clinical Oncology.

The development of human organotypic retinal cultures (HORCs) to study retinal neurodegeneration

D. Broadway, P. Sidaway, A. Osborne, 2010, British Journal of Ophthalmology.

Stones: Stones of any composition increase renal papillary density

P. Sidaway, 2015, Nature Reviews Urology.

Prostate cancer: N-Myc expression drives neuroendocrine disease

P. Sidaway, 2016, Nature Reviews Urology.

Pembrolizumab synergizes with chemotherapy

P. Sidaway, 2018, Nature Reviews Clinical Oncology.

Breast cancer: Brain metastasis detectable in CTCs

P. Sidaway, 2017, Nature Reviews Clinical Oncology.

CNS cancer: Wnt affects blood–brain barrier permeabilty

P. Sidaway, 2016, Nature Reviews Clinical Oncology.

Prostate cancer: Proton therapy delays progression

P. Sidaway, 2016, Nature Reviews Urology.

Testicular cancer: HDCT is an effective salvage approach

P. Sidaway, 2017, Nature Reviews Urology.

Alpelisib effective in advanced-stage disease

P. Sidaway, 2019, Nature Reviews Clinical Oncology.

Ivosidenib effective in IDH1-mutant AML

P. Sidaway, 2018, Nature Reviews Clinical Oncology.

Bladder cancer: Atezolizumab effective against advanced-stage disease

P. Sidaway, 2016, Nature Reviews Urology.

Mechanisms Involved in Nicotinic Acetylcholine Receptor-Induced Neurotransmitter Release from Sympathetic Nerve Terminals in the Mouse Vas Deferens

K. Brain, Damian J. Williams, T. C. Cunnane, 2011, PloS one.

University of Birmingham Mechanisms Involved in Nicotinic Acetylcholine Receptor-Induced Neurotransmitter Release from Sympathetic Nerve Terminals in the Mouse Vas Deferens

K. Brain, Damian J. Williams, T. C. Cunnane, 2011 .

Infection: Exposure to human urine decreases type 1 pili expression in uropathogenic Escherichia coli

P. Sidaway, 2015, Nature reviews. Urology.

Chronic kidney disease: Targeting connexin-43 reduces progression of CKD in mice

P. Sidaway, 2014, Nature Reviews Nephrology.

P2X7 receptor activation mediates retinal ganglion cell death in a human retina model of ischemic neurodegeneration.

D. Broadway, J. D. Rhodes, P. Sidaway, 2013, Investigative ophthalmology & visual science.

Immunotherapy: Neuropilin-1 is required for Treg stability

P. Sidaway, 2017, Nature Reviews Clinical Oncology.

Pancreatic Cancer: EGFR inhibition is effective against KRAS-wild-type disease

P. Sidaway, 2017, Nature Reviews Clinical Oncology.

Prostate cancer: New biomarker panel prognosticates patient survival

P. Sidaway, 2015, Nature Reviews Clinical Oncology.

Kidney cancer: High-affinity Fc-γ variants improve IL-2 responses

P. Sidaway, 2017, Nature Reviews Urology.

Immunogenomic features of mCRPC revealed

P. Sidaway, 2018, Nature Reviews Clinical Oncology.

Prostate cancer: Enzalutamide is superior to bicalutamide for mCRPC

P. Sidaway, 2016, Nature Reviews Urology.

Pancreatic cancer: TCGA data reveal a highly heterogeneous disease

P. Sidaway, 2017, Nature Reviews Clinical Oncology.

Prostate cancer: Effectiveness of abiraterone is unaffected by prior ADT

P. Sidaway, 2016, Nature Reviews Urology.

New targeted agents for urothelial carcinoma

P. Sidaway, 2019, Nature Reviews Clinical Oncology.

Haematological cancer: Treg predict responsiveness to blinatumomab

P. Sidaway, 2017, Nature Reviews Clinical Oncology.

BRAF-mutant ctDNA predicts outcomes

P. Sidaway, 2021, Nature Reviews Clinical Oncology.

Laparoscopic TME is non-inferior.

P. Sidaway, 2022, Nature reviews. Clinical oncology.

Lung Cancer: SABR effective against oligometastatic disease

P. Sidaway, 2017, Nature Reviews Clinical Oncology.

Medulloblastoma: prognostic subtypes revealed

P. Sidaway, 2021, Nature Reviews Clinical Oncology.

TIL infusions effective in HPV-associated cancers

P. Sidaway, 2018, Nature Reviews Clinical Oncology.

MRI, TRUS or both?

P. Sidaway, 2020, Nature reviews. Urology.

Neoadjuvant pembrolizumab shows promise

P. Sidaway, 2018, Nature Reviews Clinical Oncology.

CNS cancer: Glioblastoma subtypes revisited

P. Sidaway, 2017, Nature Reviews Clinical Oncology.

Prostate cancer: Mutations in ctDNA reflect features of metastatic disease

P. Sidaway, 2017, Nature Reviews Clinical Oncology.

Prostate cancer: Mutations in ctDNA reflect features of metastatic disease

P. Sidaway, 2017, Nature Reviews Urology.

New evidence for treatment of ALAL

P. Sidaway, 2018, Nature Reviews Clinical Oncology.

Urinary incontinence: Pacing bladder electrical activity

P. Sidaway, 2016, Nature Reviews Urology.

Haematological cancer: Ibrutinib supercharges CAR T cells

P. Sidaway, 2016, Nature Reviews Clinical Oncology.

Lymphadenectomy is not always required

P. Sidaway, 2019, Nature Reviews Clinical Oncology.

Prostate cancer: Enzalutamide plus docetaxel tested in mCRPC

P. Sidaway, 2016, Nature Reviews Urology.

Urological cancer: Non-traditional CTCs indicate prognosis

P. Sidaway, 2016, Nature Reviews Clinical Oncology.

Prostate cancer: Non-traditional CTCs indicate prognosis

P. Sidaway, 2016, Nature Reviews Urology.

Bladder cancer: Urinary EGFR and EpCAM predict cancer-specific survival

P. Sidaway, 2015, Nature Reviews Urology.

FOLFOX–HAIC active in large HCC

P. Sidaway, 2021, Nature Reviews Clinical Oncology.

Salvage radiotherapy: a new standard of care

P. Sidaway, 2020, Nature Reviews Urology.

Salvage radiotherapy: a new standard of care

P. Sidaway, 2020, Nature Reviews Clinical Oncology.

Allogeneic CAR T cells show promise

P. Sidaway, 2022, Nature Reviews Clinical Oncology.

Immunotherapy: Local chemotherapy synergizes with CTLA-4 inhibition

P. Sidaway, 2018, Nature Reviews Clinical Oncology.

Bladder cancer: Mutations in DNA-damage-repair pathways confer platinum sensitivity

P. Sidaway, 2017, Nature reviews. Urology.

Kidney cancer: Methylation of obesity-related genes is associated with prognosis

P. Sidaway, 2017, Nature Reviews Urology.

Enfortumab vedotin is safe and effective

P. Sidaway, 2021, Nature Reviews Clinical Oncology.

Urological cancer: Atezolizumab effective against advanced disease

P. Sidaway, 2016, Nature Reviews Clinical Oncology.

Head and neck cancer: Buparlisib is an effective second-line treatment

P. Sidaway, 2017, Nature Reviews Clinical Oncology.

T-DXd active in HER2-low disease

P. Sidaway, 2022, Nature Reviews Clinical Oncology.

PD-L1 positivity predicts response

P. Sidaway, 2019, Nature Reviews Clinical Oncology.

Urinary incontinence: PMC lesions correlate with LUTS in MS

P. Sidaway, 2016, Nature Reviews Urology.

Incontinence: Adding mirabegron to solifenacin improves patient outcomes

P. Sidaway, 2016, Nature Reviews Urology.

Immunotherapy: Response to nivolumab in RCC: RECISTing progression

P. Sidaway, 2016, Nature Reviews Clinical Oncology.

Setting dictates efficacy of pembrolizumab in TNBC

P. Sidaway, 2018, Nature Reviews Clinical Oncology.

SLFN11: a new synthetic lethal target?

P. Sidaway, 2018, Nature Reviews Clinical Oncology.

Lorlatinib effective in multiple settings

P. Sidaway, 2018, Nature Reviews Clinical Oncology.

Brain cancer: Temozolomide improves outcomes

P. Sidaway, 2017, Nature Reviews Clinical Oncology.

Urinary incontinence: Novel insights into the mechanism of action of mirabegron on human bladder smooth muscle

P. Sidaway, 2015, Nature Reviews Urology.

Genomics reveals distinct gastric cancer subtypes

P. Sidaway, 2018, Nature Reviews Clinical Oncology.

Breast cancer: LAG3 expression indicates favourable outcomes

P. Sidaway, 2017, Nature Reviews Clinical Oncology.

Tiragolumab active in PD-L1+ NSCLC

P. Sidaway, 2022, Nature Reviews Clinical Oncology.

Prostate cancer: HSD3B1 variant confers inferior ADT outcomes

P. Sidaway, 2016, Nature reviews. Urology.

Gilteritinib improves outcomes in AML

P. Sidaway, 2019, Nature Reviews Clinical Oncology.

HAIC-FO improves outcomes in HCC

P. Sidaway, 2022, Nature Reviews Clinical Oncology.

Diabetic nephropathy: Heparanase mediates renal injury

P. Sidaway, 2014, Nature Reviews Nephrology.

Risk factors: Acidosis predicts decline in EGFR

P. Sidaway, 2014, Nature Reviews Nephrology.

Diabetes: Epigenetic changes lead to impaired wound healing in patients with T2DM

P. Sidaway, 2015, Nature Reviews Endocrinology.

Cemiplimab effective in cutaneous SCC

P. Sidaway, 2018, Nature Reviews Clinical Oncology.

MSI-H/dMMR mCRC: ICIs in the first line?

P. Sidaway, 2021, Nature Reviews Clinical Oncology.

Chemotherapy: not for Ph+-ALL

P. Sidaway, 2020, Nature Reviews Clinical Oncology.

Prostate cancer: Enzalutamide promotes mesenchymal plasticity via Snail activation

P. Sidaway, 2017, Nature reviews. Urology.

Proteogenomics reveals molecular subtypes

P. Sidaway, 2020, Nature Reviews Clinical Oncology.

CNS cancer: Oncolytic adenovirus effective in patients with glioblastoma

P. Sidaway, 2018, Nature Reviews Clinical Oncology.

Tracing evolution reveals new biomarkers

P. Sidaway, 2019, Nature Reviews Clinical Oncology.

Urothelial carcinoma: Adjuvant chemotherapy improves outcomes after RNU

P. Sidaway, 2017, Nature reviews. Urology.

Erlotinib effective in the neoadjuvant setting

P. Sidaway, 2018, Nature Reviews Clinical Oncology.

Immunoscore provides a more accurate prognosis

P. Sidaway, 2018, Nature Reviews Clinical Oncology.

177Lu–PSMA-PET extends survival

P. Sidaway, 2021, Nature Reviews Clinical Oncology.

LAG3 inhibition improves outcomes

P. Sidaway, 2022, Nature Reviews Clinical Oncology.

Kidney cancer: Papillary features predict survival in ncRCC

P. Sidaway, 2016, Nature Reviews Clinical Oncology.

Skin cancer: Avelumab effective against Merkel-cell carcinoma

P. Sidaway, 2016, Nature Reviews Clinical Oncology.

Haematological cancer: Ponatinib in CML — keeping PACE with multiple mutations

P. Sidaway, 2016, Nature Reviews Clinical Oncology.

Genetics: Surveillance effective for TP53-mutation carriers

P. Sidaway, 2016, Nature Reviews Clinical Oncology.

Lung cancer: Ceritinib is superior to frontline chemotherapy

P. Sidaway, 2017, Nature Reviews Clinical Oncology.

Targeted therapies: Bevacizumab is effective against mesothelioma

P. Sidaway, 2016, Nature Reviews Clinical Oncology.

Ovarian cancer: Weekly or 3-weekly paclitaxel are equally effective

P. Sidaway, 2016, Nature Reviews Clinical Oncology.

The murky world of disclosures

P. Sidaway, 2018, Nature Reviews Clinical Oncology.

Risk factors: HRT increases risk of ovarian cancer

P. Sidaway, 2015, Nature Reviews Clinical Oncology.

Faecal transplantation reverses colitis

P. Sidaway, 2018, Nature Reviews Clinical Oncology.

Breast cancer: Fibroblast subtypes alter the microenvironment

P. Sidaway, 2018, Nature Reviews Clinical Oncology.

Prostate cancer: Proteomic assay predicts biochemical recurrence

P. Sidaway, 2016, Nature Reviews Urology.

Pain: Changes in urinary microbiota correlate with IC/BPS

P. Sidaway, 2017, Nature Reviews Urology.

Neutrophils: Neutrophil differentiation is autophagy dependent

P. Sidaway, 2017, Nature Reviews Immunology.

Diagnosis using methylation

P. Sidaway, 2020, Nature Reviews Clinical Oncology.

P2X7 receptor activation mediates retinal ganglion cell death in a human retina model of ischemic neurodegeneration.

D. Broadway, P. Sidaway, J. Sanderson, 2013, Investigative ophthalmology & visual science.

Urological cancer: Atezolizumab: an alternative to cisplatin?

P. Sidaway, 2017, Nature Reviews Clinical Oncology.

Bladder cancer: Atezolizumab: an alternative to cisplatin?

P. Sidaway, 2017, Nature Reviews Urology.

Haematological cancer: Daratumumab proves effective in patients with newly diagnosed multiple myeloma

P. Sidaway, 2018, Nature Reviews Clinical Oncology.